In this episode of Biotech Innovators, Dr. Jeanne Loring, Professor Emeritus at Scripps Research Institute and Founder, CSO, and Chair of the SAB at Aspen Neuroscience, joins host Josh Judkins to discuss her work in stem cell research, Parkinson's disease, her partnership with the Summit for Stem Cell, entrepreneurship, and the importance of support and mentorship in academia and business. 

This content is offered for informational purposes only. The opinions stated in this podcast are that of the speaker and do not constitute or imply an endorsement by Thermo Fisher Scientific.

When university and industry researchers work in tandem to conquer big challenges in medicine, they can achieve much more together than they ever could apart. Sue Fletcher, a pioneer in RNA therapeutics and Chief Scientific Officer at PYC Therapeutics, knows this firsthand.

She has spent decades in the field and is the co-developer of some revolutionary genetic therapies for treating rare diseases. Here, Dr. Fletcher answers questions about her work in this field, her incredible career, and how she’s inspiring young scientists in this complex area.

This content is offered for informational purposes only. The opinions stated in this podcast are that of the speaker and do not constitute or imply an endorsement by Thermo Fisher Scientific.

Innovation is critical to the future of healthcare, and it can lead to better patient outcomes, improved well-being, and overall better population health. Unfortunately, too many brilliant biomedical concepts never reach patients due to a lack of funding, technical difficulties, or legislative difficulties.

In this episode of the Building Biotechs series of the Biotech Innovators podcast, we welcome Kurt Gielen, the co-founder and chief business officer of Medace, a unique biomedical incubator committed to turning biomedical research into reality. He talks about the complex process of biomedical innovation, how Medace supports promising biotech startups, and the potential challenges these innovations may face.

This content is offered for informational purposes only. The opinions stated in this podcast are that of the speaker and do not constitute or imply an endorsement by Thermo Fisher Scientific.

One of the greatest unexplored spaces in the world, is the microbiome: a bustling network of trillions of microorganisms living inside each of us. If we could learn more about them, the advances we’d make in healthcare and other fields would be incredible.  This line of thinking is what spurred Thomas Jarvie, former CEO and Co-Founder, to start Shoreline Biome, maker of the most complete end-to-end microbiome sample prep kits on the market. Hear his incredible story in this Biotech Innovators podcast.

This content is offered for informational purposes only. The opinions stated in this podcast are that of the speaker and do not constitute or imply an endorsement by Thermo Fisher Scientific.

When it comes to biotech, both the academic and industry settings are crucial in developing novel medicines. Dr. Brent Cezairliyan has experienced both sides of biotech, first through an academic career exploring bacterial pathogenesis, and now in his administrative role at Octagon Therapeutics. The company, headquartered in Cambridge, Massachusetts, focuses on autoimmune disease treatments. By developing targeted approaches to the inflammatory nature of the immune system, they hope their advances in biotech help future scientists navigate the field for years to come.

This content is offered for informational purposes only. The opinions stated in this podcast are that of the speaker and do not constitute or imply an endorsement by Thermo Fisher Scientific.

Ever wonder how a small business can pivot when a global pandemic occurs? Josh Arant, co-founder MAKO Medical, discusses how they disrupted the status quo with passion and a heartfelt desire to give more to their clients. Then, how they rose to meet the needs of their community and country during a time of crisis.

This content is offered for informational purposes only. The opinions stated in this podcast are that of the speaker and do not constitute or imply an endorsement by Thermo Fisher Scientific.

Cell and gene therapies may well be some of the most important recent advancements in modern medicine. The way they work, however, is very complex and completely different from any pill that simply addresses symptoms. So, who are the pioneers in this field and what dares them to ask, “what if”?  In this episode of the Biotech Innovators podcast, learn from Ainslie Little, senior vice president of corporate strategy at BlueRock Therapeutics, and how her company’s cell & gene platform is breaking new ground in this important space.

This content is offered for informational purposes only. The opinions stated in this podcast are that of the speaker and do not constitute or imply an endorsement by Thermo Fisher Scientific.

Dr. Schiffman is a pediatric hematologist-oncologist and co-founder/CEO of PEEL Therapeutics headquartered in Salt Lake City, UT, USA and Haifa, Israel. It's a clinical-stage biotech company with a serendipitous origin story and a bright future. The company's name is the Hebrew word for elephant—an animal with amazing cancer-fighting genes that ignited the imaginations of Dr. Schiffman and his partners, sparking a new approach to fighting disease in humans starting with cancer and inflammatory diseases. PEEL's work is inspired by evolution and focuses on the science and the interconnectedness of all life on Earth. They aim to turn millions of years of evolution into the medicine humans need today.

This content is offered for informational purposes only. The opinions stated in this podcast are that of the speaker and do not constitute or imply an endorsement by Thermo Fisher Scientific.

We're living during a time of enormous technological breakthroughs and innovation is the key to shaping the world. 

However, when it comes to the biotech industry and biotechnological drug development,  science has to always be at the center of them.

In this episode of the Biotech Innovators podcast, we welcome Samir Ounzain, the co-founder & CEO of Haya Therapeutics. They talk about Samir's path from watching Jurassic Park in a dark theater as a kid to studying the dark matter of the human genome in a lab – and eventually, to the founding of Haya Therapeutics.

This content is offered for informational purposes only. The opinions stated in this podcast are that of the speaker and do not constitute or imply an endorsement by Thermo Fisher Scientific.